与胰高血糖素样肽-1（GLP-1）受体激动剂相比，双重葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1（GIP/GLP-1）受体激动剂的降压疗效
Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists.
作者信息
Grenet Guillaume, Gougeon Arthur, Salzwedel Douglas M, Jauca Ciprian D, Wright James M
机构信息
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada.
Laboratoire de Biométrie et Biologie Evolutive, UMR CNRS 5558, Université Lyon 1, Lyon, France.
出版信息
Cochrane Database Syst Rev. 2025 Apr 16;4(4):CD016144. doi: 10.1002/14651858.CD016144.
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To compare the blood pressure effects of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists with the blood pressure effects of glucagon-like peptide-1 (GLP-1) receptor agonists.
摘要
这是一项Cochrane系统评价（干预措施）的方案。目标如下：比较双重葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1（GIP/GLP-1）受体激动剂与胰高血糖素样肽-1（GLP-1）受体激动剂对血压的影响。
相似文献
1
Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists.与胰高血糖素样肽-1（GLP-1）受体激动剂相比，双重葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1（GIP/GLP-1）受体激动剂的降压疗效
Cochrane Database Syst Rev. 2025 Apr 16;4(4):CD016144. doi: 10.1002/14651858.CD016144.
2
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.双重葡萄糖依赖性胰岛素促胰岛素多肽（GIP）和胰高血糖素样肽-1（GLP-1）受体激动剂替西帕肽：一种新的代谢治疗前景。
Cardiovasc Diabetol. 2021 Nov 24;20(1):225. doi: 10.1186/s12933-021-01412-5.
3
How May GIP Enhance the Therapeutic Efficacy of GLP-1?GIP 如何增强 GLP-1 的治疗效果？
Trends Endocrinol Metab. 2020 Jun;31(6):410-421. doi: 10.1016/j.tem.2020.02.006. Epub 2020 Mar 16.
4
Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?为何在无2型糖尿病的肥胖成年人中，胰高糖素样肽-1（GLP-1）激动剂联合葡萄糖依赖性促胰岛素多肽（GIP）和/或胰高血糖素原（GCG）激动剂比单独使用GLP-1激动剂具有更强的减重效果？
Diabetes Obes Metab. 2025 Mar;27(3):1079-1095. doi: 10.1111/dom.16106. Epub 2024 Nov 26.
5
[A new era for incretins : from GLP-1 receptor agonists to co-agonists and poly-agonists].肠促胰岛素的新时代：从胰高糖素样肽-1受体激动剂到协同激动剂和多靶点激动剂
Rev Med Liege. 2024 Sep;79(9):605-612.
6
Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.与治疗 2 型糖尿病的 GLP-1 或双重 GIP/GLP-1 受体激动剂替西帕肽相关的主要不良心血管事件和中风风险：系统评价和荟萃分析。
Eur Stroke J. 2024 Sep;9(3):530-539. doi: 10.1177/23969873241234238. Epub 2024 Feb 23.
7
The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update.通向三重激动剂的道路：胰高血糖素样肽 1、葡萄糖依赖性胰岛素释放肽和胰高血糖素受体——更新。
Endocrinol Metab (Seoul). 2024 Feb;39(1):12-22. doi: 10.3803/EnM.2024.1942. Epub 2024 Feb 14.
8
Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.替尔泊肽：一种葡萄糖依赖性胰岛素促泌多肽（GIP）和胰高血糖素样肽-1（GLP-1）双重激动剂，正在开发用于治疗 2 型糖尿病。
Expert Rev Endocrinol Metab. 2020 Nov;15(6):379-394. doi: 10.1080/17446651.2020.1830759. Epub 2020 Oct 8.
9
A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy.一种长效葡萄糖依赖性促胰岛素多肽受体激动剂可改善胰高血糖素样肽-1受体激动剂疗法的胃肠道耐受性。
Diabetes Obes Metab. 2024 Nov;26(11):5474-5478. doi: 10.1111/dom.15875. Epub 2024 Aug 27.
10
Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice.葡萄糖依赖性胰岛素释放多肽和胰高血糖素样肽受体激动剂降低体重的效果在 RAMP1/3 KO 小鼠中比 WT 小鼠更有效。
Eur J Pharmacol. 2023 Sep 15;955:175912. doi: 10.1016/j.ejphar.2023.175912. Epub 2023 Jul 14.
本文引用的文献
1
Mapping the effectiveness and risks of GLP-1 receptor agonists.绘制胰高血糖素样肽-1受体激动剂的有效性和风险图谱。
Nat Med. 2025 Mar;31(3):951-962. doi: 10.1038/s41591-024-03412-w. Epub 2025 Jan 20.
2
Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants.全球糖尿病患病率和治疗趋势 1990 年至 2022 年：基于 14100 万参与者的 1108 项人群代表性研究的汇总分析。
Lancet. 2024 Nov 23;404(10467):2077-2093. doi: 10.1016/S0140-6736(24)02317-1. Epub 2024 Nov 13.
3
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.用于治疗2型糖尿病和肥胖症的GLP-1单受体、双受体和三受体激动剂：一项叙述性综述
EClinicalMedicine. 2024 Aug 30;75:102782. doi: 10.1016/j.eclinm.2024.102782. eCollection 2024 Sep.
4
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.GLP-1 类药物治疗 2 型糖尿病和肥胖症的疗效和安全性。
Diabetes Care. 2024 Nov 1;47(11):1873-1888. doi: 10.2337/dci24-0003.
5
Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.胰高血糖素样肽-1 受体激动剂可适度降低伴或不伴糖尿病患者的血压：一项荟萃分析和荟萃回归研究。
Diabetes Obes Metab. 2024 Jun;26(6):2209-2228. doi: 10.1111/dom.15529. Epub 2024 Mar 20.
6
Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.全球范围内 1990 年至 2022 年体重不足和肥胖趋势：对 3663 项具有 2.22 亿儿童、青少年和成年人代表性的人群研究进行的汇总分析。
Lancet. 2024 Mar 16;403(10431):1027-1050. doi: 10.1016/S0140-6736(23)02750-2. Epub 2024 Feb 29.
7
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.胰高血糖素样肽-1受体激动剂对2型糖尿病血糖控制、体重和血脂水平的比较疗效：系统评价和网状Meta分析
BMJ. 2024 Jan 29;384:e076410. doi: 10.1136/bmj-2023-076410.
8
The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis.司美格鲁肽对 2 型糖尿病患者血压的影响：系统评价和荟萃分析。
Endocrine. 2024 Mar;83(3):571-584. doi: 10.1007/s12020-023-03636-9. Epub 2023 Dec 15.
9
Obesity Management in Adults: A Review.成人肥胖管理：综述。
JAMA. 2023 Nov 28;330(20):2000-2015. doi: 10.1001/jama.2023.19897.
10
Beyond glycemia: Comparing tirzepatide to GLP-1 analogues.超越血糖：比较替西帕肽与 GLP-1 类似物。
Rev Endocr Metab Disord. 2023 Dec;24(6):1089-1101. doi: 10.1007/s11154-023-09825-1. Epub 2023 Aug 1.
Zotero 插件